Risk Of Developing Liver Cancer After HCV Treatment

Tuesday, May 21, 2013

DDW 2013 Video - Simeprevir (Tmc435) Plus Sofosbuvir (Gs-7977) With or Without Ribavirin HCV GT 1 Null Responders.




DDW 2013 Late Breaker

Eric J. Lawitz, MD discusses his late-breaking poster: Sa2073: Svr4 Results of a Once Daily Regimen of Simeprevir (Tmc435) Plus Sofosbuvir (Gs-7977) With or Without Ribavirin (RBV) in HCV GT 1 Null Responders. Dr. Lawitz is Medical Director, principal investigator for Alamo Medical research

http://www.healio.com/hepatology.

No comments:

Post a Comment